Cigna’s Ever­north just made a move to boost Hu­mi­ra biosim­i­lar use

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) 

Cigna’s health ser­vices arm Ever­north said on Thurs­day that it plans to of­fer a cheap­er copy­cat of Ab­b­Vie’s block­buster drug Hu­mi­ra for $0, but it prob­a­bly won’t move the nee­dle on slow biosim­i­lar up­take.

The move comes af­ter Cigna’s ri­val CVS Health part­nered with drug­mak­er San­doz to sell a Hu­mi­ra biosim­i­lar and kicked the brand-name drug from its na­tion­al for­mu­la­ry.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER